Wednesday, October 08, 2014 9:38:39 AM
http://seekingalpha.com/pr/11255465-chimerixs-brincidofovir-shows-potential-survival-benefit-in-adenovirus-infection?app=n
Chimerix's Brincidofovir Shows Potential Survival Benefit in Adenovirus Infection
Wed October 8, 2014 6:30 AM|GlobeNewswire | About: CMRX
DURHAM, N.C., Oct. 8, 2014 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, announced today preliminary data for its investigational antiviral brincidofovir (BCV, CMX001) showing improved survival for patients with adenovirus in the open-label pilot portion of the Phase 3 AdVise Trial. These data will be presented at the annual meeting of the Infectious Diseases Society of America (IDSA), IDWeek, on Saturday, October 11 at 10:50 a.m. EDT in Philadelphia, PA.
The preliminary survival analysis data, based on 48 evaluable patients from the ongoing AdVise Trial, showed a mortality rate of 35 percent compared with the historic rates of up to 80 percent mortality in the first month after diagnosis. A majority of subjects also had suppression or clearance of adenovirus from the blood. There is currently no approved treatment for adenovirus, an infection that can progress rapidly in patients with a weakened immune system due to disease or medications.
"When progressive adenovirus infection occurs in immunocompromised patients, they deteriorate, and the infection can be fatal in up to four of every five cases," said Dr. Jo-Anne Young, Professor of Medicine and Medical Director of the Program in Transplant Infectious Disease at the University of Minnesota. "In these very sick patients who were treated with brincidofovir, nearly two-thirds of the patients survived the first few weeks when we have historically seen the highest mortality. These results are encouraging and warrant the continued evaluation of brincidofovir as a promising antiviral for this life-threatening infection, for which a treatment is desperately needed."
Chimerix (CMRX) initiated AdVise in March 2014 based on potency observed in vitro and on clinical data from a Phase 2 trial and a large expanded access trial which showed the potential for improved clinical outcomes. As of September 19th, 48 subjects had enrolled in AdVise, with 35 percent mortality observed to date (17 of 48) with a median duration of observation of 57 days for living patients.
The trial is enrolling pediatric and adult patients with adenovirus infection who receive brincidofovir twice weekly for twelve weeks. Baseline information and at least two months of follow up are available for 26 subjects. Of those 26 patients, 23 had measurable viral loads at study entry, and three patients had no virus detectable in the blood but had diagnosed adenovirus infection. Fourteen of the 23 patients with viremia at study entry achieved undetectable viral loads during treatment. Twelve of the 26 patients died.
Over half of the subjects were hematopoeitic cell transplant (HCT) recipients with disseminated disease, but solid organ transplant recipients and patients undergoing chemotherapy were also enrolled. Over one-third of the subjects (10 of 26) had a second active infection with another DNA virus in addition to adenovirus, including BK virus (27 percent), cytomegalovirus (19 percent) and Epstein Barr virus (8 percent).
The safety and tolerability profile of brincidofovir in these initial subjects was similar to other studies of brincidofovir in immunocompromised patients with complicated medical issues, with only three subjects discontinuing due to adverse events. Of the six subjects who enrolled in the study with adenovirus-related diarrhea, three reported improvement of symptoms and three remained stable.
"These data reinforce the potential for brincidofovir to significantly impact the mortality from adenovirus infections and provide data to support the design of the pivotal trial," said W. Garrett Nichols, M.D., M.S., Chief Medical Officer of Chimerix. "It is also important that, particularly in patients who are struggling with adenovirus infection, more than one-third of patients have more than one DNA virus, which underscores the need for a safe and broad-spectrum antiviral."
About AdVise
AdVise is a Phase 3 clinical trial to evaluate the safety and efficacy of brincidofovir for the treatment of adenovirus infection. In March 2014, Chimerix initiated the open-label pilot portion of the study. Chimerix is working closely with the U.S. Food and Drug Administration (FDA) on the design of a pivotal Phase 3 study that will be a continuation of this pilot study. Adenovirus infection can be associated with a mortality rate of up to 80 percent in patients who are undergoing hematopoeitic cell transplants (HCT), and there are no therapies approved to treat this infection. Adenovirus causes upper respiratory infections, including the common cold in individuals with a functional immune system, but it can lead to graft failure, severe pneumonia, hepatitis or death in those with a weakened immune system, such as patients who have undergone a transplant.
About Brincidofovir (BCV, CMX001)
Chimerix's lead product candidate, brincidofovir, is an oral nucleotide analog that has shown in vitro antiviral activity against all five families of DNA viruses that affect humans, including viruses in the herpes virus family and adenovirus. Brincidofovir has not been associated with kidney or bone marrow toxicity in nearly 900 patients treated to date, side effects that can be treatment limiting with currently available antivirals. Building on the positive Phase 2 results in cytomegalovirus (CMV) prevention, Chimerix initiated the Phase 3 SUPPRESS trial in 2013. If positive, data from SUPPRESS will support Chimerix's initial regulatory submission for brincidofovir for the prevention of CMV infection in adult hematopoietic cell transplant (HCT) recipients. Chimerix recently initiated AdVise, a Phase 3 trial in adenovirus, which is an often-fatal viral infection with no approved treatment; enrollment is ongoing for the pilot portion of the trial. Chimerix is also working with the Biomedical Advanced Research and Development Authority (BARDA) to develop brincidofovir as a medical countermeasure against smallpox. Brincidofovir has received Fast Track designation from the FDA for CMV, adenovirus, and smallpox.
All I say is IMHO and not to be construed as investment advice. I know nothing, as informed frequently by my wife.
Recent CMRX News
- Chimerix to Present at H.C. Wainwright 26th Annual Global Investment Conference • GlobeNewswire Inc. • 09/03/2024 11:00:00 AM
- Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 08/30/2024 08:05:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/13/2024 08:05:51 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 11:22:48 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 11:03:39 AM
- Chimerix Reports Second Quarter 2024 Financial Results and Provides Operational Update • GlobeNewswire Inc. • 08/13/2024 11:00:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/09/2024 05:26:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/09/2024 04:01:08 PM
- Chimerix to Report Second Quarter 2024 Financial Results and Provide an Operational Update on August 13, 2024 • GlobeNewswire Inc. • 08/06/2024 11:00:00 AM
- Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 07/05/2024 08:05:00 PM
- Chimerix to Participate in Fireside Chat at Jefferies Global Healthcare Conference • GlobeNewswire Inc. • 05/30/2024 11:00:00 AM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/06/2024 04:15:24 AM
- Chimerix Reports First Quarter 2024 Financial Results and Provides Operational Update • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- Chimerix to Report First Quarter 2024 Financial Results and Provide an Operational Update on May 1, 2024 • GlobeNewswire Inc. • 04/24/2024 11:00:00 AM
- Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/16/2024 08:05:00 PM
- Chimerix Appoints Marc D. Kozin to Board of Directors • GlobeNewswire Inc. • 03/21/2024 11:00:00 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 02/29/2024 02:20:57 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 01:24:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 12:58:26 PM
- Chimerix Reports Fourth Quarter and Year End 2023 Financial Results and Provides Operational Update • GlobeNewswire Inc. • 02/29/2024 12:00:00 PM
- Chimerix to Present at TD Cowen 44th Annual Health Care Conference • GlobeNewswire Inc. • 02/27/2024 12:00:00 PM
- Chimerix to Report Fourth Quarter and Year End 2023 Financial Results and Provide an Operational Update on February 29, 2024 • GlobeNewswire Inc. • 02/22/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/17/2024 01:02:47 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/17/2024 01:01:37 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/17/2024 01:00:36 AM
FEATURED Element79 Gold Corp. Reports Significant Progress in Community Relations and Development Efforts in Chachas, Peru • Oct 9, 2024 10:30 AM
Unitronix Corp Launches Share Buyback Initiative • UTRX • Oct 9, 2024 9:10 AM
BASANITE INDUSTRIES, LLC RECEIVES U.S. PATENT FOR ITS BASAFLEX™ BASALT FIBER COMPOSITE REBAR AND METHOD OF MANUFACTURING • BASA • Oct 9, 2024 7:30 AM
BNCM COMPLETES MERGER WITH DELEX HEALTHCARE • BNCM • Oct 8, 2024 9:54 AM
CBD Life Sciences, Inc. (CBDL) Reaches Unprecedented Heights With Explosive Growth and Strategic Expansion in 2024 • CBDL • Oct 8, 2024 8:00 AM
Unitronix Corp. to Invest $3 Million in USA Unity Coin Project • UTRX • Oct 7, 2024 7:08 AM